Mearini Luigi, Zucchi Alessandro, Costantini Elisabetta, Bini Vittorio, Nunzi Elisabetta, Porena Massimo
Urology Department, University of Perugia, Perugia, Italy.
Urol Int. 2010;85(2):166-72. doi: 10.1159/000316944. Epub 2010 Jun 18.
Radical prostatectomy (RP) in patients with locally advanced (cT3) prostate cancer (PCa) is considered an optional therapy.
To evaluate outcomes of surgery for cT3 disease and to compare results with those of patients treated for cT1-T2 PCa.
Data of 74 consecutive patients with cT3 N0M0 PCa who underwent RP were compared to those of 425 consecutive unselected patients who underwent surgery for cT1-T2 N0M0 disease.
cT3: The pathological report showed a pathological downstaging in 16.3% of cases. Continence rate was 65.5%, potency rate was 38.8%, 5-year PSA-free survival was 61.9%, 5-year cancer-specific survival was 95.2%. cT1-T2: The pathological report showed a clinical downstaging in 39.1%. Continence rate was 70.8%, potency rate was 56.2%, 5-year PSA-free survival was 67.4%, 5-year cancer-specific survival was 96.0%.
cT3 PCa presents challenges for the uro-oncologist since standard treatment is still under debate. RP in well-informed patients is a procedure with acceptable morbidity and should be at least a first part of a multimodality approach.
对于局部晚期（cT3）前列腺癌（PCa）患者，根治性前列腺切除术（RP）被认为是一种可选择的治疗方法。
评估cT3期疾病的手术效果，并与cT1 - T2期PCa患者的治疗结果进行比较。
将74例连续接受RP的cT3 N0M0 PCa患者的数据与425例连续接受cT1 - T2 N0M0疾病手术的未选择患者的数据进行比较。
cT3期：病理报告显示16.3%的病例病理分期下降。控尿率为65.5%，性功能保留率为38.8%，5年无PSA生存率为61.9%，5年癌症特异性生存率为95.2%。cT1 - T2期：病理报告显示39.1%的病例临床分期下降。控尿率为70.8%，性功能保留率为56.2%，5年无PSA生存率为67.4%，5年癌症特异性生存率为96.0%。
cT3期PCa给泌尿肿瘤学家带来了挑战，因为标准治疗仍存在争议。对于充分知情的患者，RP是一种发病率可接受的手术，应至少作为多模式治疗方法的第一部分。
